MCLA-129 clinical trials

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

This study is looking into a new drug, MCLA-129, for some advanced cancers like lung or stomach cancer. It will see how safe and effective it is, both by itself and with other treatments. It's for people who haven't responded to previous treatments.